Molecular Chaperones as Prognostic Markers of Neuroblastoma by Yung-Feng Liao et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
Molecular Chaperones as 
Prognostic Markers of Neuroblastoma 
Yung-Feng Liao et al.*  
Institute of Cellular and Organismic Biology, Academia Sinica 
Taipei, 
 Taiwan 
1. Introduction 
Neuroblastoma (NB) is a childhood tumor derived from sympathoadreanal lineage of the 
neural crest progenitor cells, and is the most common malignant disease of infancy, 
accounting for 96% of cases occurred before the age of 10 (Gurney et al., 1995, Maris and 
Matthay, 1999). The neuroblastoma cells exhibit characteristics of undifferentiated cells and 
often metastasize to distant organs (Maris and Matthay, 1999, Maris et al., 2007). 
Approximately, 60% of patients diagnosed with NB display a stage IV disease and a very 
poor prognosis. The 5-year survival rate of NB patients is no more than 30%, even with 
aggressive therapy (Nishihira et al., 2000). As a result, 50% of the NB patients die from this 
disease that continues to be one of the most difficult challenges among pediatric tumors. 
NB is quite a heterogeneous tumor and presents a broad clinical and biologic spectrum 
ranging from highly undifferentiated tumors with very poor outcomes to the most 
differentiated benign ganglioneuroma or NBs with high probability of spontaneous 
regression and hence favorable prognosis. The clinical presentation of NB can be 
categorized into three distinct patterns based on the tumor histology: (i) life-threatening 
progression; (ii) maturation to ganglioneuroblastoma (GNB) or ganglioneuroma (GN); and 
(iii) spontaneous regression (Pritchard and Hickman, 1994). Taking other biological 
variables into account, NBs can be categorized into two groups in terms of prognosis 
(Brodeur, 2003, Woods et al., 1992). One, the favorable NB, is associated with young age and  
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early stage at diagnosis, triploid karyotypes with whole chromosome gains, and excellent 
clinical outcome despite minimal or no therapy. The other, the unfavorable NB, is 
associated with older age and advanced stage, and pseudodiploid karyotypes with 
structural changes including deletion of 1p or 11q, unbalanced gain of 17q and/or 
amplification of the MYCN proto-oncogene. Patients with unfavorable NBs usually have a 
very poor outcome despite multimodality therapies including bone marrow 
transplantation. Furthermore, we have also previously shown that the biologic 
characteristics of NB tumors would significantly influence the surgical decision (Hsu et 
al., 2006). The role of gross total resection of the primary tumor, a high-risk operation, has 
been controversial in the treatment of NB, especially in advanced NB. We demonstrated 
that gross total resection of the primary tumor could carry favorable outcome only in a 
specific group of NB with certain biomarkers (Hsu et al., 2006). These lines of evidence 
suggest that a more detailed understanding of the clinical and biologic characteristics of 
NB is imperative for the selection of appropriate therapeutic intervention on these tumors 
in order to achieve effective treatment without unnecessary complications. In this review, 
we will briefly overview the molecular mechanisms implicated in the tumorigenesis of NB 
and discuss the pathological roles of three chaperone proteins in this tumor. A model will 
then be proposed to illustrate the aberrant functions of chaperone proteins in 
predisposing neuroblastic cells into the initiation of NB. 
2. The tumorigenesis of neuroblastoma 
Aberrant embryonic development of sympathetic nervous system has been suggested to 
underlie the tumorigenesis of NB. The molecular characterization of clinically relevant 
prognostic markers is likely to shed light on the molecular mechanisms governing the 
neuroblast development and lead to the identification of novel therapeutic targets of NB. 
Since NB exhibits great tendency to differentiate, intensive induction therapy of NB has 
been widely attempted to improve outcomes. Recent evidence suggests that NB cells exhibit 
capacity of differentiating into mature cells and can be forced to differentiate upon the 
treatment of retinoic acid, butyric acid, or cisplatin (Ijiri et al., 2000, Tonini, 1993). A number 
of molecules normally expressed during embryonic development, including HNK-1, 
neuropeptide Y, tyrosine hydroxylase, TrkA and CD44, are found in NB (Hoehner et al., 
1996, Israel, 1993), suggesting that the tumorigenesis of NB could be a divergence of the 
embryonic development of the sympathetic nervous system. On the other hand, NB cells 
with better prognosis are often found to express markers indicative of cell differentiation, 
such as HNK-1 and TrkA (Cooper et al., 1992, Nakagawara et al., 1993). It is thus plausible 
that the tumorigenesis of NB might result from the defect in the differentiation of embryonic 
NB cells (Tonini, 1993). Interestingly, NB can regress spontaneously by apoptosis (Ijiri et al., 
2000, Pritchard and Hickman, 1994). The expression of pro-apoptotic genes is evident in 
NB,that correlates with favorable prognosis, and the survival rate of NB patients is 
proportional to the expression levels of these genes (Hoehner et al., 1997). Inducers of 
differentiation, including retinoid acid and cisplatin, could promote apoptosis in NB cells 
(Tonini, 1993), and NB cells expressing TrkA may undergo cell death when deprived of 
nerve growth factor (NGF) (Nakagawara et al., 1993), suggesting that the deficient apoptosis 
of embryonic NB cells could lead to the tumorigenesis of NB. However, what factors may 
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contribute to the regulation of NB cell differentiation or apoptosis is still unclear. Accumulated 
evidence has suggested that apoptosis and differentiation of NB cells might occur 
simultaneously (Ijiri et al., 2000, Tonini, 1993). Consistently, NB cells expressing TrkA can be 
induced to differentiate in the presence of NGF, while undergo apoptosis upon withdrawal of 
NGF (Nakagawara et al., 1993). It is thus conceivable that factors mediating the tumorigenesis 
of NB would affect the differentiation and apoptosis of the NB cells simultaneously.  
NB tumors are highly vascular and autonomously produce a variety of angiogenic factors, 
such as VEGF, bFGF, Ang-2, TGF-β, and PDGF-A, that are commonly found in advanced-
stage tumors (Eggert et al., 2000). Although it is still debatable (Canete et al., 2000), the 
vascular index, as expressed by numbers of vessels per square millimeter of tissue area, has 
been shown to correlate with the adverse prognosis of NB patients (Meitar et al., 1996). 
Furthermore, the obstruction of angiogenesis may induce differentiation and apoptosis in 
NB (Wassberg et al., 1999), suggesting that the angiogenic factors produced by NB could 
also play an important role in the differentiation and apoptosis of NB cells. 
Together, these data suggest that failure of either differentiation or regression by apoptotic 
death of NB cells is critical for the development of NB. This notion can be further supported 
by these findings (i) that the high frequency of spontaneous differentiation and regression 
can be observed in 4S tumors as well as those detected by mass screening; (ii) that the 
neuroblastic tumors (NTs) in adrenal glands obtained from non-afflicted infants at autopsy 
indicates a high incidence of unrecognized spontaneous resolution; (iii) that expression of 
apoptosis-related genes has been demonstrated in NB; and (iv) that NB patients  with higher 
apoptotic index have better prognosis. Along these lines, we will describe the functions of 
three chaperone proteins that are implicated in the differentiation of NB. The alteration of 
their functions, either individually or combinarotially, could result in the propensity for the 
neuroblastic cells to transform and initiate the tumorigenesis of NB. 
Here, we summarize the roles of three newly identified favorable prognostic markers, 
whose functionality as chaperones are well-established, in the pathogenesis of NB. Although 
these biomarkers, including calreticulin, glucose-regulated protein 78, and glucose-
regulated protein 75, could be localized to different intracellular organelles, our recent 
studies have provided compelling evidence demonstrating that these biomarkers share an 
emerging function in actively governing the neuronal differentiation of neuroblastic cells. 
These new findings thus propose a model in which some chaperone proteins might not 
simply be a protein guardian in securing the normal folding of cellular proteins but could 
vigorously engage in crucial cellular functions by themselves. 
3. Molecular chaperones of tumorigenesis 
The enhanced expression of molecular chaperones have been found in a variety of tumors, and 
is often associated with an unfavorable prognosis and resistance to therapy (Calderwood et al., 
2006). These molecular chaperones at high levels can promote tumorigenesis through 
facilitating the accumulation of overexpressed and mutated oncogenes and inhibiting 
apoptosis of tumor cells. According to Hanahan and Weinbeg (Hanahan and Weinberg, 2000), 
the tumorigenesis can be organized into six phenotypic changes in cellular functions: (i) 
autonomy in growth signaling; (ii) resistance to growth inhibition; (iii) evasion of apoptosis; 
(iv) unlimited proliferative potential; (v) persistent angiogenesis; and (vi) tissue invasion and 
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metastasis. The increased expression of molecular chaperones thus could not only allow tumor 
cells acquire malignant capabilities, but also actively play a role in most stages of tumor 
development and the acquisition of drug resistance.   
3.1 Calreticulin 
Calreticulin (CRT) is a molecular chaperone primarily localized to endoplasmic reticulum, 
and has emerged as an early stage marker of NB. Although CRT is best known for its critical 
role in securing the correct folding and maturation of nascent proteins (Ellgaard and 
Helenius, 2003), it also involves in the regulation of Ca2+ homeostasis, the modulation of 
integrin-dependent adhesion, the alteration of Ca2+-elicited signaling, and the inhibition of 
the transcriptional activities of steroid receptors (Coppolino et al., 1997, Dedhar et al., 1994, 
Michalak et al., 1999). The expression of CRT can be up-regulated under stress conditions 
and apoptosis, suggesting CRT as a stress protein (Nakamura et al., 2000). Consistent with 
these findings, mice deficient of CRT exhibit significant brain defects (Rauch et al., 2000), 
suggesting an essential role of CRT in the embryonic development of nervous system.  
The role of CRT in tumorigenesis has just begun to be elucidated, evidenced by the 
differential expression and localization of CRT in malignant versus non-malignant tissues. 
The nuclear localization of CRT in hepatocellular carcinoma and various carcinomas, but not 
in nonmalignant liver tissue, suggests that the interaction of calreticulin and nuclear matrix 
could be critical for the uncontrolled proliferation of carcinomas (Yoon et al., 2000). 
Furthermore, up-regulated expression of CRT can be observed in breast cancers, suggesting 
that CRT is pivotal for the malignant progression of carcinomas (Bini et al., 1997, Franzen et 
al., 1997). Interestingly, vasostatin, the N-terminal fragment of CRT, and the full-length CRT 
have been shown to suppress tumor growth by directly targeting endothelial cells to inhibit 
angiogenesis (Pike et al., 1998, Pike et al., 1999). A recent report further demonstrates that 
CRT can serve as a recognition ligand for LDL receptor-related protein (LRP) and signal for 
the removal of apoptotic cells in a CRT/LRP-dependent manner (Gardai et al., 2005). These 
findings depict dual functions of intracellular CRT and extracellular CRT in tumorigenesis. 
The former is likely to promote tumor growth by entering nuclei to alter the function of 
transcriptional machinery, while the latter could target specific surface receptors to hinder 
the growth of malignant cells. 
The essential role of CRT in the differentiation of NB cells has recently been established. 
The up-regulated expression of CRT in NB cells, coincident with the alteration of integrin 
profile on the surface, is particularly prominent upon differentiation (Combaret et al., 
1994, Gladson et al., 1997, Rozzo et al., 1993, Coppolino et al., 1997), substantiating an 
essential function of CRT in mediating integrin-dependent calcium signaling. CRT in 
differentiating NB cells is localized to plasma membrane and could play an essential role 
in neurite outgrowth (Xiao et al., 1999a, Xiao et al., 1999b). These results suggest that CRT 
in NB, unlike in other carcinomas, can be re-distributed to cell surface to antagonize 
tumor growth upon induced differentiation. To verify this hypothesis, we evaluate the 
association of clinicopathologic factors and patient survival with the expression of CRT in 
patients with NB to determine whether CRT could affect the tumor behavior of NB (Hsu 
et al., 2005a). Our data show that positive CRT expression is strongly correlated with 
differentiated histologies in sixty-eight NBs. Its expression is also closely associated with 
known favorable prognostic factors such as detected from mass screening, younger age 
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(≤1 year) at diagnosis and early clinical stages, but is inversely correlated with MYCN 
amplification. Overall, NB patients with higher levels of CRT fare significantly better in 
long-term survival, substantiating CRT as an independent prognostic factor. Moreover, 
CRT expression also predicted better survival in patients with advanced-stage NB, and its 
absence predicted poor survival in patients whose tumor had no MYCN amplification. 
Altogether, CRT could actively play a part in the differentiation, apoptosis and 
angiogenesis of NB as well as the pathogenesis of NB. 
3.2 Glucose-regulated protein 78 
Glucose-regulated protein 78 (GRP78) is a member of the family of heat shock protein 70 
(HSP70) that is localized at the endoplasmic reticulum (ER) (Gething, 1999). Like other ER-
resident chaperones, GRP78 is essential for the correct folding and translocation of newly-
synthesized secretory proteins across the ER membrane, and is also required for the 
retrotranslocation of aberrant and misfolded polypeptides destined for degradation in 
proteasome (Gething, 1999). In addition to being a constituent of the quality control system 
in ER, GRP78 also contributes to the maintenance of Ca2+ homeostasis (Chevet et al., 1999). 
GRP78 expression in normal adult organs is generally maintained at low levels and could 
become escalated in tumors (Dong et al., 2004), suggesting that GRP78 is required for the 
propagation of cancers. Consistent with this finding, tumor progression in GRP78 
heterozygous mice is significantly attenuated, accompanied by a longer latency period, 
reduced tumor size, and increased tumor apoptosis (Lee, 2007). Accumulated evidence also 
suggest that GRP78 overexpression could renders various cancers resistance to 
chemotherapy (Li and Lee, 2006). These findings provide the rationales for targeting GRP78 
as an anticancer approach that could be used in conjunction with standard therapeutic 
agents to improve the prognosis. 
Like other HSP70 family members, GRP78 is constitutively expressed at high levels in 
neuroepithelial cells of the neural tube, suggesting that GRP78 and other HSP70 proteins 
could play significant roles in the development and differentiation of neural tissue (Barnes 
and Smoak, 2000, Walsh et al., 1997). By using a rat pheochromocytoma cell line PC12 as a 
cellular model of neuroblastoma, the levels of GRP78 protein are significantly enhanced in 
PC12 cells that are induced by nerve growth factor (NGF) to differentiate (Satoh et al., 2000). 
The overexpression of exogenous GRP78 can further augment the neurite outgrowth 
induced by NGF, while the down-regulation of GRP78 blocks the NGF-induced neurite 
outgrowth (Satoh et al., 2000), suggesting a functional synergism between NGF signaling 
and GRP78 function with respect to neuronal differentiation. Consistently, the inhibition of 
cell death in NGF-deprived neuronal cells reduces of the levels of GRP78 transcripts, 
suggesting a functional role of GRP78 in neuronal cell death (Aoki et al., 1997). The 
possibility thus exists that GRP78 could affect the differentiation and apoptosis of NB and 
may have a role in the tumor behavior of this cancer. In supporting this view, data from our 
lab have confirmed the clinical importance of GRP78 in NB. In a cohort of 68 neuroblastic 
tumors, forty (58.8%) of them display positive GRP78 expression by immunohistochemistry, 
and the positive GRP78 immunostaining is tightly correlated with differentiation histology 
of tumor and early clinical stages, but inversely correlated with MYCN amplification (Hsu 
et al., 2005b). Our findings also suggest that GRP78 expression could be an independent 
prognostic biomarker for favorable outcome in NB patients. Given that the differential roles 
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of GRP78 in NB and other solid tumors, it would become increasingly critical to assess 
GRP78 expression level for the proper management of patients with NB versus other types 
of cancers. 
3.3 Glucose-regulated protein 75 
Glucose-regulated protein 75 (GRP75) is a member of heat shock protein 70 family and is 
first cloned from the cytoplasmic fraction of normal mouse fibroblast (Wadhwa et al., 1993). 
GRP75, also known as mortalin-2, is a member of mitochondrial molecular chaperones, but 
could also resides in other organelles, such as ER, plasma membrane, cytoplasmic vesicles, 
and cytosol (Kaul et al., 2002). GRP75 carries multiple cellular functions ranging from stress 
response, intracellular trafficking, antigen processing, control of cell proliferation, 
differentiation, and tumorigenesis (Wadhwa et al., 2002b). It has been shown that GRP75 is 
distributed in a pancytoplasmic pattern in normal cells but could be redistributed into a 
perinuclear mode in transformed cells (Wadhwa et al., 1995). The versatilities of GRP75’s 
functions can also be exemplified by its interactions with many cellular proteins, including 
metabolic enzymes (e.g. diphosphomevalonate decarboxylase), mitochondrial proteins (e.g. 
voltage-dependent anion channel 1), and proteins involved in proliferation and 
differentiation (e.g. FGF-1, MKK7, and p53) (Wadhwa et al., 2003, Schwarzer et al., 2002, 
Wadhwa et al., 1998).  
The tumorigenic role of GRP75 is shown by its colocalization with p53 in the perinuclear 
region of various cancers, possibly through taking part in the suppression of p53 expression 
(Wadhwa et al., 2002a, Wadhwa et al., 1998). GRP75 can thus serve as a functional chelator 
of p53 by sequestering it in cytoplasm to suppress p53-dependent gene expression. 
Consistent with these data, overexpression of GRP75 is found to be crucial for the changes 
from immortal to malignant phenotypes, leading to aggressive proliferative potential 
(Czarnecka et al., 2006). The expression of GRP75 is evidently up-regulated in a large 
number of tumorigenic human cell lines, implicating its overexpression as a marker of cell 
transformation (Wadhwa et al., 2006). In the acute myeloid leukemia HL-60 cells, the level of 
GRP75 is down-regulated upon differentiation, while overexpression of GRP75 is able to 
attenuate RA-induced differentiation and prevent apoptosis (Xu et al., 1999). Furthermore, 
GRP75 has been shown to be critical for the malignancy of breast cancer cells, and cells with 
higher levels of GRP75 are prone to exhibit an anchorage-independent phenotype and form 
tumors in nude mice (Wadhwa et al., 2006). Together, GRP75 actively involves in the 
molecular mechanisms governing the carcinogenesis of various tumors and could represent 
an ideal candidate for gene therapy. 
The exact role of GRP75 in the tumorigenesis of neuroblastoma is still unclear. We have 
employed two-dimensional differential gel electrophoresis (2-D DIGE) to identify GRP75 as 
one of the most dramatically up-regulated proteins in differentiated NB cells. 
Immunohistochemical analyses of NB tissues further reveal that positive GRP75 
immunostaining is strongly correlated with differentiated histologies, mass-screened tumors 
and early clinical stages, but inversely correlated with MYCN amplification. Consistent with 
these data, univariate and multivariate survival analyses demonstrate that GRP75 
expression is an independent favorable prognostic factor. Our data substantiate an essential 
role of GRP75 in the differentiation of neuroblastoma and establish a novel function of 
GRP75 in promoting the differentiation of NB cells. Whether GRP75 localized at different 
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intracellular compartments can play distinctive cellular functions is not clear. Nevertheless, 
our data demonstrate for the first time that the change in the intracellular distribution of 
GRP75 coincides with the development of neuronal phenotypes of differentiated NB cells, 
strongly suggesting a functional role of GRP75 in neuronal differentiation.  
4. Conclusion 
Current data have clearly suggested that the tumorigenesis of NB is controlled by a complex 
mechanism and is distinct from that of other cancers. This process could be driven by the 
intricate interactions among many gene products in multiple pathways. The best-known 
examples of molecular chaperones involved in the regulation of neuronal differentiation, 
such as CRT, GRP78, and GRP75, also turn out to be favorable prognostic markers of NB, 
paving the way for us to unveil the functional roles of molecular chaperones in the 
tumorigenesis of NB. A recent study has shown that GRP75 and GRP78, another favorable 
prognostic marker of NB (Hsu et al., 2005b), could bind to RHAMM with an associated 
downregulation of RHAMM in Jurkat cells (Kuwabara et al., 2006). The GRP75/78-RHAMM 
complex could then bind to the microtubules to stabilize the microtubules in the interphase 
and prevent the depolymerization of microtubules for the progression of mitosis (Kuwabara 
et al., 2006). The essential role of RHAMM in neurite extension has been suggested (Nagy et 
al., 1995), and the expression of RHAMM has been linked to the progression and metastasis 
of a variety of cancers (Maxwell et al., 2005). The possibility thus exists that the 
pancytoplasmic GRP75 in differentiating NB cells, along with GRP78, may prevent these 
cells from engaging into mitosis by binding with and downregulating RHAMM while 
promoting the neurite formation simultaneously. These findings thus suggest that the non-
chepraone effects of these molecular chaperones might play an even bigger role in 
tumorigenesis of NB and other cancers.  
A number of molecular chaperones of ER and mitochondria, such as CRT, GRP78, GRP75, 
and GRP94, whose expression is affected by tumorigenic pathways could be re-distributed 
outside their primary resident organelles, such as plasma membrane, neurites, and nuclei, 
upon differentiation. Data from others and our own labs have clearly demonstrated the “off-
site” localization of these molecular chaperones. There may also be other mechanisms for 
the re-localization of chaperones to the nuclei and neurites that are associated with the 
cellular transformation. In contrast, molecular chaperones, such as calnexin in ER, that are 
constitutively expressed despite oncogenic transformation would mostly remain immotile 
during differentiation of NB. It remains to be determined whether the off-site expression of 
molecular chaperones is restricted to specific types of cancer and what fractions of these 
chaperones are presented on different cellular locations in tumor cells. Nonetheless, in 
certain cancers, the surface-localized GRP78 has been utilized as a beacon to deliver 
therapeutic agents specifically into cancer cells (Fu and Lee, 2006). Biologic factors that 
predict a favorable outcome for neuroblastoma patients are usually associated with 
differentiation or regression of neuroblastoma cells and early clinical stages. It remains to be 
investigated whether the expression of these differentiation-associated molecular 
chaperones, including HSP45, GRP78, GRP75, and calreticulin, in neuroblastic tumors 
would be sufficient to counteract the MYCN-elicited tumorigenesis of NB. In summary, 
molecular chaperones that are expressed in increased amounts in NB during differentiation 
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could play an essential role in NB by slowing down its autonomous growth through 
promoting neuronal differentiation. The increased abundance of molecular chaperones in 
differentiated NB cells also offers tempting targets for the development of gene therapy that 
can attenuate the malignant phenotype of NB. 
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